Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease

IRCCS San Raffaele30 enrolled

Overview

Patients with coronary artery disease have an abnormal cardiac metabolism. The hypothesis of this study is that shifting cardiac metabolism from free fatty acids to glucose will improve myocardial ischemia

The present study will evaluate the effect of free fatty acid inhibition with Trimetazidine on silent myocardial ischemia and total ischemic burden in coronary artery disease patients with type II diabetes. Patients will undergo ambulatory ECG monitoring at baseline and will be randomized to receive on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. Patients will repeat the ambulatory ECG monitoring at the end of the study

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Coronary Artery Disease Type II Diabetes Mellitus

Interventions

TrimetazidineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: coronary artery disease type II diabetes mellitus - Exclusion Criteria: unstable coronary artery syndromes impaired liver and kidney function \-

Outcomes

Primary Outcomes

total ischemic burden

silent ischemia

Secondary Outcomes

symptomatic myocardial ischemia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.